The National Institute for Health and Care Excellence (NICE) has approved a groundbreaking treatment for blood cancer patients in England—belantamab mafodotin. This innovative drug fights multiple myeloma by acting as a Trojan horse, allowing it to enter cancer cells and release a potent molecule to kill them. Patients will receive this therapy through infusions every three weeks, and it is expected to extend the survival period significantly compared to traditional treatments. With the NHS becoming the first health service to offer this drug, around 1,500 patients yearly are anticipated to benefit from it.
About 1,500 patients a year in England with multiple myeloma will benefit from the pioneering Trojan horse drug, belantamab mafodotin, which is a game-changer in cancer treatment.
This new treatment, which works by delivering a lethal molecule inside cancer cells, has the potential to significantly extend the lives of patients suffering from multiple myeloma.
Collection
[
|
...
]